ArticleBMC health services research2016
Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.
Article in BMC health services research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies.Frontiers in nutrition · 2021Pooled it
- Effects of Chenpi Jiaosu on serum metabolites and intestinal microflora in a dyslipidemia population: a randomized controlled pilot trial.Frontiers in endocrinology · 2025Trial
- A Bioequivalence Study of Ezetimibe/Rosuvastatin Fixed Dose Combination (10 mg/10 mg) Versus the Individual Formulations Taken Concomitantly.Advances in therapy · 2023Trial
- Effects of intracoronary low-dose prourokinase administration on ST-segment elevation in patients with myocardial infarction and a high thrombus burden: a randomized controlled trial.The Journal of international medical research · 2022Trial
- Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders".International journal of molecular sciences · 2019Trial
- Distinct Dietary Patterns Are Differentially Associated with Dyslipidemia Among Middle-Aged and Older Adults in Southern China.Nutrients · 2026Article
- Associations of occupational heat exposure with dyslipidemia among petrochemical workers: insights from a 9-year longitudinal study.BMC public health · 2026Article
- The association between T4 and TSH with lipid profile is attenuated in patients with established dyslipidemia.BMC endocrine disorders · 2026Article
- Fat distribution, inflammatory mechanisms, and cardiovascular disease risk: mediation analysis based on the Framingham risk score.BMC cardiovascular disorders · 2025Article
- Differential expression of glucose metabolism and circadian rhythm-related genes in patients with acute myocardial infarction and their clinical significance.Scientific reports · 2025Article
- Influence of systemic immunoinflammatory index on major adverse cardiovascular events in patients with coronary heart disease with heart failure as assessed by propensity score matching.European journal of medical research · 2025Article
- Madecassoside mitigates acute myocardial infarction injury by activating the PKCB/SPARC signaling pathway.Acta pharmacologica Sinica · 2025Article
- Effect of chest pain center accreditation on timely reperfusion and in-hospital mortality for STEMI in China.Scientific reports · 2025Article
- Development and validation of machine learning models based on stacked generalization to predict psychosocial maladjustment in patients with acute myocardial infarction.BMC psychiatry · 2025Article
- Expert Consensus on the Diagnosis and Management of Carotid Atherosclerotic Plaque: Pathophysiology, Clinical Management, and Preventive Approaches.International journal of medical sciences · 2025Review
- Random Forest Analysis of Out-of-Pocket Health Expenditures Associated with Cardiometabolic Diseases, Lifestyle, Lipid Profile, and Genetic Information in São Paulo, Brazil.Healthcare (Basel, Switzerland) · 2024Article
- Article
- GAN-Augmented Naïve Bayes for identifying high-risk coronary artery disease patients using CT angiography data.Scientific reports · 2024Article
- Association between homocysteine levels and hyperlipidemia prevalence as well as all-cause mortality of hyperlipidemia patients in the US population: results from NHANES database.Frontiers in cardiovascular medicine · 2024Article
- Pharmacoeconomic evaluation of stroke and myocardial infarction prevention in hypertensive patients: Markov model based on the ACCOMPLISH trial.The Journal of international medical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLifestyle and dietary changes reflect an ongoing epidemiological transition in China, with cardiovascular disease (CVD) playing an ever-increasing role in China's disease burden. This study assessed the burden of CVD and the potential value of lipid and blood pressure control strategies in China.
methodsWe estimated the likely burden of CVD between 2016 and 2030 and how expanded use of lipid lowering and blood pressure control medication would impact that burden in the next 15 years. Accounting for the costs of drug use, we assessed the net social value of a policy that expands the utilization of lipid and blood pressure lowering therapies in China.
resultsRises in prevalence of CVD risk and population aging would likely increase the incidence of acute myocardial infarctions (AMIs) by 75 million and strokes by 118 million, while the number of CVD deaths would rise by 39 million in total between 2016 and 2030. Universal treatment of hypertension and dyslipidemia patients with lipid and blood pressure lowering therapies could avert between 10 and 20 million AMIs, between 8 and 30 million strokes, and between 3 and 10 million CVD deaths during the 2016-2030 period, producing a positive social value net of health care costs as high as $932 billion.
conclusionsIn light of its aging population and epidemiological transition, China faces near-certain increases in CVD morbidity and mortality. Preventative measures such as effective lipid and blood pressure management may reduce CVD burden substantially and provide large social value. While the Chinese government is implementing more systematic approaches to health care delivery, prevention of CVD should be high on the agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.